368 related articles for article (PubMed ID: 20579470)
1. Long-term management of erythrodermic psoriasis with anti-TNF agents.
Romero-Maté A; García-Donoso C; Martinez-Morán C; Hernández-Núñez A; Borbujo J
Dermatol Online J; 2010 Jun; 16(6):15. PubMed ID: 20579470
[TBL] [Abstract][Full Text] [Related]
2. Etanercept: new indication. For ankylosing spondylitis: another option.
Prescrire Int; 2005 Jun; 14(77):92-3. PubMed ID: 15981387
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
[TBL] [Abstract][Full Text] [Related]
4. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis.
Heikkilä H; Ranki A; Cajanus S; Karvonen SL
Arch Dermatol; 2005 Dec; 141(12):1607-10. PubMed ID: 16365275
[No Abstract] [Full Text] [Related]
5. Two years of experience with etanercept in recalcitrant psoriasis.
Ahmad K; Rogers S
Br J Dermatol; 2007 May; 156(5):1010-4. PubMed ID: 17408393
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study.
Gisondi P; Cotena C; Tessari G; Girolomoni G
J Eur Acad Dermatol Venereol; 2008 Mar; 22(3):341-4. PubMed ID: 18005022
[TBL] [Abstract][Full Text] [Related]
7. Sustained efficacy of ustekinumab in refractory erythrodermic psoriasis after failure of antitumor necrosis factor therapies.
Castiñeiras I; Fernández-Diaz L; Juárez Y; Lueiro M
J Dermatol; 2012 Aug; 39(8):730-1. PubMed ID: 22364316
[No Abstract] [Full Text] [Related]
8. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis.
De Rycke L; Baeten D; Kruithof E; Van den Bosch F; Veys EM; De Keyser F
Arthritis Rheum; 2005 Jul; 52(7):2192-201. PubMed ID: 15986349
[TBL] [Abstract][Full Text] [Related]
9. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
10. [Anti-TNF alfa therapy in ankylosing spondylitis].
Cravo AR; Tavares V; Da Silva JC
Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
[TBL] [Abstract][Full Text] [Related]
11. Life-threatening pustular and erythrodermic psoriasis responding to infliximab.
Lewis TG; Tuchinda C; Lim HW; Wong HK
J Drugs Dermatol; 2006 Jun; 5(6):546-8. PubMed ID: 16774108
[TBL] [Abstract][Full Text] [Related]
12. Treatment of erythrodermic psoriasis with etanercept.
Esposito M; Mazzotta A; de Felice C; Papoutsaki M; Chimenti S
Br J Dermatol; 2006 Jul; 155(1):156-9. PubMed ID: 16792768
[TBL] [Abstract][Full Text] [Related]
13. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept.
Braun J; Baraliakos X; Listing J; Sieper J
Arthritis Rheum; 2005 Aug; 52(8):2447-51. PubMed ID: 16052578
[TBL] [Abstract][Full Text] [Related]
14. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
15. [Effects of infliximab and etanercept, two types of anti-tumor necrosis factor-alpha inhibitor on serum level of matrix metalloproteinase 3 expression in patients with ankylosing spondylitis].
Yang CH; Huang F; Deng XH; Zhang JL; Zhang LY; Guo JH; Liang DF; Wang LS; Zhang YM
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(35):2451-4. PubMed ID: 17156669
[TBL] [Abstract][Full Text] [Related]
16. Anti-TNF-alpha therapy in childhood pustular psoriasis.
Pereira TM; Vieira AP; Fernandes JC; Antunes H; Basto AS
Dermatology; 2006; 213(4):350-2. PubMed ID: 17135745
[No Abstract] [Full Text] [Related]
17. Consecutive use of different biological therapies in the treatment of psoriasis.
Costanzo A; Papoutsaki M; Mazzotta A; Chimenti S
Br J Dermatol; 2007 Aug; 157(2):394. PubMed ID: 17553044
[No Abstract] [Full Text] [Related]
18. Infliximab-induced psoriasis in treatment of Crohn's disease-associated ankylosing spondylitis: case report and review of 142 cases.
Famenini S; Wu JJ
J Drugs Dermatol; 2013 Aug; 12(8):939-43. PubMed ID: 23986169
[TBL] [Abstract][Full Text] [Related]
19. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
Yip L; Harrison S; Foley P
Australas J Dermatol; 2008 Aug; 49(3):152-5. PubMed ID: 18638223
[TBL] [Abstract][Full Text] [Related]
20. Erythroderma in the era of biological therapies.
Zattra E; Belloni Fortina A; Peserico A; Alaibac M
Eur J Dermatol; 2012; 22(2):167-71. PubMed ID: 22321651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]